Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

Daniel C Julien, Steven Behnke, Guankui K Wang, Gordon K Murdoch, Rodney A Hill

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and malignant spread of cancerous cells. Many mAbs are in various stages of testing and 11 are currently marketed in the US or Europe for the treatment of cancers that express particular antigens such as human epidermal growth factor receptor-2, CD20, epidermal growth factor receptor and vascular endothelial growth factor. Strategies to conjugate mAbs to toxins, radioactive isotopes and chemotherapeutic drugs to improve efficacy are under intense investigation and numerous immunoconjugates have been studied in the clinical setting. However, the molecules have limitations, and so nanomaterials (NMs), which potentially offer more flexibility of design and functionality in providing platforms for binding of multiple therapeutic agents in a single structure, are being examined as an alternative. Studies utilizing mAb-targeted NMs have shown that they exhibit focused targeting, improved pharmacokinetics and improved "passive" drug delivery via leaky vasculature. Nevertheless, before they can be utilized to treat cancer, potential NM toxicity must be thoroughly investigated. Thus, rigorous testing of NM-mAb conjugates in both in vitro and in vivo systems is underway to determine how NM-mAb conjugates will interact with cells and tissues of the body. In this review, we discuss the broad range of nanomaterials that are under investigation as potential platforms for the presentation of mAbs either as single therapeutics or in combination with other drugs and their advantages and limitations in specifically targeting cancer.
Original languageEnglish
Pages (from-to)467-478
Number of pages12
JournalmAbs
Volume3
Issue number5
DOIs
Publication statusPublished - 2011

Fingerprint

Nanostructures
Monoclonal Antibodies
Neoplasms
Pharmaceutical Preparations
Immunoconjugates
Immunotoxins
Epidermal Growth Factor Receptor
Radioisotopes
Vascular Endothelial Growth Factor A
Epitopes
Pharmacokinetics
Cell Proliferation
Antigens
Therapeutics

Cite this

Julien, Daniel C ; Behnke, Steven ; Wang, Guankui K ; Murdoch, Gordon K ; Hill, Rodney A. / Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer. In: mAbs. 2011 ; Vol. 3, No. 5. pp. 467-478.
@article{0d654cfcf2e841219da1e12bb45dedda,
title = "Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer",
abstract = "Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and malignant spread of cancerous cells. Many mAbs are in various stages of testing and 11 are currently marketed in the US or Europe for the treatment of cancers that express particular antigens such as human epidermal growth factor receptor-2, CD20, epidermal growth factor receptor and vascular endothelial growth factor. Strategies to conjugate mAbs to toxins, radioactive isotopes and chemotherapeutic drugs to improve efficacy are under intense investigation and numerous immunoconjugates have been studied in the clinical setting. However, the molecules have limitations, and so nanomaterials (NMs), which potentially offer more flexibility of design and functionality in providing platforms for binding of multiple therapeutic agents in a single structure, are being examined as an alternative. Studies utilizing mAb-targeted NMs have shown that they exhibit focused targeting, improved pharmacokinetics and improved {"}passive{"} drug delivery via leaky vasculature. Nevertheless, before they can be utilized to treat cancer, potential NM toxicity must be thoroughly investigated. Thus, rigorous testing of NM-mAb conjugates in both in vitro and in vivo systems is underway to determine how NM-mAb conjugates will interact with cells and tissues of the body. In this review, we discuss the broad range of nanomaterials that are under investigation as potential platforms for the presentation of mAbs either as single therapeutics or in combination with other drugs and their advantages and limitations in specifically targeting cancer.",
keywords = "cancer immunotherapy nanomaterial nanomedicine Medicine, Research & Experimental MEDICINE, RESEARCH & EXPERIMENTAL Research & Experimental Medicine",
author = "Julien, {Daniel C} and Steven Behnke and Wang, {Guankui K} and Murdoch, {Gordon K} and Hill, {Rodney A}",
note = "Cited References Count:110|V29HX|LANDES BIOSCIENCE|1806 RIO GRANDE ST, AUSTIN, TX 78702 USA|Julien, Daniel C.|Behnke, Steven|Wang, Guankui|Murdoch, Gordon K.|Hill, Rodney A.|ISI Document Delivery No.:V29HX",
year = "2011",
doi = "10.4161/mabs.3.5.16089",
language = "English",
volume = "3",
pages = "467--478",
journal = "mAbs",
issn = "1942-0862",
publisher = "Landes Bioscience",
number = "5",

}

Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer. / Julien, Daniel C; Behnke, Steven; Wang, Guankui K; Murdoch, Gordon K; Hill, Rodney A.

In: mAbs, Vol. 3, No. 5, 2011, p. 467-478.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

AU - Julien, Daniel C

AU - Behnke, Steven

AU - Wang, Guankui K

AU - Murdoch, Gordon K

AU - Hill, Rodney A

N1 - Cited References Count:110|V29HX|LANDES BIOSCIENCE|1806 RIO GRANDE ST, AUSTIN, TX 78702 USA|Julien, Daniel C.|Behnke, Steven|Wang, Guankui|Murdoch, Gordon K.|Hill, Rodney A.|ISI Document Delivery No.:V29HX

PY - 2011

Y1 - 2011

N2 - Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and malignant spread of cancerous cells. Many mAbs are in various stages of testing and 11 are currently marketed in the US or Europe for the treatment of cancers that express particular antigens such as human epidermal growth factor receptor-2, CD20, epidermal growth factor receptor and vascular endothelial growth factor. Strategies to conjugate mAbs to toxins, radioactive isotopes and chemotherapeutic drugs to improve efficacy are under intense investigation and numerous immunoconjugates have been studied in the clinical setting. However, the molecules have limitations, and so nanomaterials (NMs), which potentially offer more flexibility of design and functionality in providing platforms for binding of multiple therapeutic agents in a single structure, are being examined as an alternative. Studies utilizing mAb-targeted NMs have shown that they exhibit focused targeting, improved pharmacokinetics and improved "passive" drug delivery via leaky vasculature. Nevertheless, before they can be utilized to treat cancer, potential NM toxicity must be thoroughly investigated. Thus, rigorous testing of NM-mAb conjugates in both in vitro and in vivo systems is underway to determine how NM-mAb conjugates will interact with cells and tissues of the body. In this review, we discuss the broad range of nanomaterials that are under investigation as potential platforms for the presentation of mAbs either as single therapeutics or in combination with other drugs and their advantages and limitations in specifically targeting cancer.

AB - Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and malignant spread of cancerous cells. Many mAbs are in various stages of testing and 11 are currently marketed in the US or Europe for the treatment of cancers that express particular antigens such as human epidermal growth factor receptor-2, CD20, epidermal growth factor receptor and vascular endothelial growth factor. Strategies to conjugate mAbs to toxins, radioactive isotopes and chemotherapeutic drugs to improve efficacy are under intense investigation and numerous immunoconjugates have been studied in the clinical setting. However, the molecules have limitations, and so nanomaterials (NMs), which potentially offer more flexibility of design and functionality in providing platforms for binding of multiple therapeutic agents in a single structure, are being examined as an alternative. Studies utilizing mAb-targeted NMs have shown that they exhibit focused targeting, improved pharmacokinetics and improved "passive" drug delivery via leaky vasculature. Nevertheless, before they can be utilized to treat cancer, potential NM toxicity must be thoroughly investigated. Thus, rigorous testing of NM-mAb conjugates in both in vitro and in vivo systems is underway to determine how NM-mAb conjugates will interact with cells and tissues of the body. In this review, we discuss the broad range of nanomaterials that are under investigation as potential platforms for the presentation of mAbs either as single therapeutics or in combination with other drugs and their advantages and limitations in specifically targeting cancer.

KW - cancer immunotherapy nanomaterial nanomedicine Medicine, Research & Experimental MEDICINE, RESEARCH & EXPERIMENTAL Research & Experimental Medicine

U2 - 10.4161/mabs.3.5.16089

DO - 10.4161/mabs.3.5.16089

M3 - Article

VL - 3

SP - 467

EP - 478

JO - mAbs

JF - mAbs

SN - 1942-0862

IS - 5

ER -